论文部分内容阅读
口服抗胆硷脂酶药治疗重症肌无力,因吸收不完全,有时不能维持疗效。即使与类固醇和免疫抑制剂合用也是如此。作者报道这类病人1例,并对这一难题提出一种新的处理。病人27岁,女性,因吞咽与发音困难18个月,经腾西龙试验证实为重症肌无力,先后进行了胸腺切除术、放射性治疗、新斯的明每日300mg、吡啶斯的明每日600mg、阿苯胺每日30mg、强的松龙每日75mg、硫唑嘌呤每日150mg先后换血浆疗法共6次等均无显效,并出现呼吸困难、潮气量降至90ml而行气管切开人工呼吸。经用新斯的明皮下和静脉注射(最高剂量2mg),间歇使用1周后好转。潮气量达250ml,停用人工呼吸。后将新斯的明改为持续皮下注入,每日10～25mg,病情进一步好转。但停用后病情又加
Oral cholecystokinin treatment of myasthenia gravis, due to incomplete absorption, and sometimes can not maintain efficacy. Even with steroids and immunosuppressive agents. The authors reported 1 such patient and proposed a new treatment of this problem. The patient was 27 years old and had difficulty swallowing and pronunciation for 18 months. Herbs were proved to be myasthenia gravis by the test of Toxins. Thymopectomy, radiotherapy, neostigmine 300 mg daily, pyridostigmine daily 600mg, aniline 30mg daily, prednisolone daily 75mg, azathioprine 150mg per day for plasma therapy a total of 6 times were ineffective, and dyspnea, tidal volume dropped to 90ml and tracheotomy manual Breathe. Subcutaneous and intravenous injection of neostigmine (maximum dose of 2mg), intermittent use after 1 week improved. Tidal volume of 250ml, disable artificial respiration. After the neostigmine into continuous subcutaneous injection daily 10 ~ 25mg, the condition further improved. But disabled after the disease plus